SequelSEC

REGENXBIO Inc. RGNX

Biological Products, (No Diagnostic Substances) · CIK 0001590877 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$174.48M
Fiscal year ended 2026-06-30
Operating income
-$164.15M
Fiscal year ended 2026-06-30
Free cash flow
-$249.67M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$385.01MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$7.46Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth104.5%82th
CapEx / revenue1.4%26th
Operating margin-94.6%70th
Current ratio2.38x30th
SBC / revenue20.3%34th
FCF margin-74.1%65th
Net margin-113.8%64th
R&D / revenue133.9%38th

REGENXBIO Inc. (RGNX) reported revenue of $174.48M and net income of -$196.43M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from REGENXBIO Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

REGENXBIO Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$174.48M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$164.15M
Net income-$196.43M
Research & development$229.14M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$85.56M
Selling & marketingUnavailable

Balance

REGENXBIO Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$36.49M
Total assets$386.62M
Current assets$236.16M
Total liabilities$314.85M
Current liabilities$82.62M
Total equity incl. NCI$71.76M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$106.75M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$15.55M

Cash flow

REGENXBIO Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$246.67M
Capital expenditures$2.99M
Investing cash flow$216.34M
Financing cash flow-$12.74M
Net change in cash-$43.07M
Stock-based compensation$35.04M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$15.37M

Derived

REGENXBIO Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$249.67M
Gross marginUnavailable
Operating margin-94.1%
FCF margin-143.1%
SBC / revenue20.1%
Current ratio2.86x
Revenue YoY growth12.0%
Net margin-112.6%
R&D / revenue131.3%
CapEx / revenue1.7%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RGNX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.